Cencora, Inc. $COR Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its stake in Cencora, Inc. (NYSE:COR) by 0.5% during the 3rd quarter, Holdings Channel.com reports. The fund owned 1,475,170 shares of the company’s stock after selling 6,784 shares during the period. Dimensional Fund Advisors LP’s holdings in Cencora were worth $460,997,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Cornerstone Wealth Group LLC boosted its holdings in shares of Cencora by 1.3% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after purchasing an additional 30 shares during the last quarter. Security Financial Services INC. boosted its holdings in Cencora by 2.6% in the third quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after acquiring an additional 33 shares during the last quarter. Hemington Wealth Management grew its position in Cencora by 12.0% during the third quarter. Hemington Wealth Management now owns 327 shares of the company’s stock valued at $102,000 after acquiring an additional 35 shares during the period. Quadcap Wealth Management LLC increased its stake in Cencora by 1.5% during the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after acquiring an additional 36 shares during the last quarter. Finally, Howard Capital Management Inc. raised its holdings in shares of Cencora by 2.5% in the 3rd quarter. Howard Capital Management Inc. now owns 1,499 shares of the company’s stock worth $468,000 after purchasing an additional 37 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Evercore decreased their target price on Cencora from $440.00 to $420.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Barclays boosted their price objective on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a research note on Friday, February 13th. Bank of America cut their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a research note on Monday, January 5th. TD Cowen upped their price target on shares of Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Robert W. Baird set a $415.00 price target on Cencora in a report on Tuesday, January 13th. Eleven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $399.00.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the transaction, the chief executive officer directly owned 66,726 shares in the company, valued at $23,669,713.98. This represents a 7.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares of the company’s stock, valued at approximately $8,173,111.10. This represents a 12.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 15,220 shares of company stock worth $5,282,867 in the last three months. 0.38% of the stock is owned by insiders.

Cencora Price Performance

COR opened at $368.48 on Thursday. Cencora, Inc. has a twelve month low of $248.59 and a twelve month high of $377.54. The firm has a market cap of $71.68 billion, a price-to-earnings ratio of 44.29, a PEG ratio of 1.73 and a beta of 0.68. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The company has a fifty day simple moving average of $353.51 and a 200 day simple moving average of $335.52.

Cencora (NYSE:COR) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same period in the prior year, the company posted $3.73 EPS. The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. Equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s payout ratio is currently 28.85%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.